The Food and Drug Administration (FDA) has not yet approved any medication containing CBD, except for one prescription drug used to treat seizures associated with the tuberous sclerosis complex, Lennox-Gastaut syndrome, and Dravet syndrome in human patients. The FDA is actively working to answer questions about the science, safety, and quality of products containing cannabis and compounds derived from cannabis, particularly CBD. The FDA has not approved any other cannabis product, derived from cannabis or cannabidiol (CBD) currently available on the market. As such, the FDA has concluded that it is prohibited to introduce or deliver for introduction into interstate commerce any food (including any food or feed for animals) to which THC or CBD has been added.
The agency has tested the chemical content of cannabinoid compounds in some of the products and found that many did not contain the levels of CBD they claimed.The FDA has not approved the use of CBD in animals, and concerns about CBD products with unproven medical claims and of unknown quality apply equally to CBD products marketed to animals. In the past, the FDA sent warning letters to companies that illegally sold CBD products and claimed to prevent, diagnose, treat, or cure serious diseases, such as cancer.Since CBD is an unapproved drug, the FDA has not had the opportunity to evaluate CBD residues in foods or to establish an adequate period of abstinence. To date, there is a lack of data on the waste that can be produced when food-producing animals consume CBD products. The FDA has warned companies to stop selling CBD products that they claim are intended to prevent, diagnose, treat, mitigate or cure serious diseases such as cancer, Alzheimer's disease, psychiatric disorders and diabetes.The FDA recognizes the significant public interest in cannabis and compounds derived from cannabis, in particular CBD.
However, based on available evidence, the FDA has concluded that neither THC nor CBD is safe for consumption. It is important to note that the FDA has not approved any other cannabis product derived from cannabis or cannabidiol (CBD) currently available on the market.